Answers are grounded in this paper and cite their sources.
We herein report a 78-year-old woman with Gaucher disease (GD) who was initially diagnosed with GD type 1, had been receiving long-term enzyme replacement therapy since 58 years old, and developed neurological manifestations in her 70s. The neurological manifestations included myoclonic seizures and progressive cognitive decline. Although it is rare for GD patients to first develop neurologic manifestations at such an advanced age, physicians engaged in long-term care for GD patients should be alert for this possibility.
No takes yet. Share an insight, caveat, or question.
Yamaguchi-Takegami et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: